Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 May 13;12(5):e8102.
doi: 10.7759/cureus.8102.

Flexural Exanthema From Enfortumab Vedotin

Dinesh Keerty  1 , Laura Graham  2 , Elizabeth Haynes  2 , Timothy N Hembree  2
Affiliations
Case Reports

Flexural Exanthema From Enfortumab Vedotin

Dinesh Keerty et al. Cureus. .

Abstract

Urothelial malignancies are commonly treated with platinum-based therapies. Newer trials have tested antimitotic therapies such as enfortumab vedotin as viable treatment therapy for refractory malignany. Enfortumab vedotin targets nectin-4, a member of a family of calcium-dependent, immunoglobulin-like adhesion molecules found in adherens junctions and expressed in various epithelial malignancies, including bladder, breast, lung, ovarian, head/neck, and esophageal cancers. We present a case of a patient with symmetrical drug-related intertriginous and flexural exanthema secondary to enfortumab. He was successfully treated with topical corticosteroids. Cutaneous toxicity appears to be a common adverse reaction in this growing class of antibody-drug conjugates.

Keywords: adverse drug reaction; drug rash; urothelial malignancy.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Bilateral flexural exanthema of feet
See this image and copyright information in PMC

References

    1. Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma. Wu S, Adamson AS. https://escholarship.org/uc/item/4j44w7w6 Dermatol Online J. 2019;25:1–3. - PubMed
    1. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Challita-Eid PM, Satpayev D, Yang P, et al. https://cancerres.aacrjournals.org/content/76/10/3003.article-info. Cancer Res. 2016;76:3003–3013. - PubMed
    1. Padcev (enfortumab vedotin) [prescribing information] [Mar;2020 ];https://astellas.us/docs/PADCEV_label.pdf Northbrook, IL: Astellas Pharma US, Inc December. 2019
    1. EV-201: a single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy. Rosenberg JE, Balar A, O'Donnell P, et al. https://doi.org/10.1093/annonc/mdy283.127 Ann Oncol. 2018;29:0.

Publication types

LinkOut - more resources